arrow
S

Sally C. M. Lau

princess margaret cancer centre, university health network, 610 university ave., toronto, on m5g 2m9, canada
H指数:19
被引数:1,395

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases

一项回顾性分析,探讨治疗前中性粒细胞与淋巴细胞比值与晚期非小细胞肺癌伴肝转移患者免疫检查点抑制剂疗效的关联。

2025-10-220
OA
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

塔拉他玛单抗联合PD-L1抑制剂作为一线维持疗法在广泛期小细胞肺癌患者化疗免疫治疗后的安全性与活性(DeLLphi-303):一项多中心、非随机、1b期研究

2025-09-080
PRE
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
CANCER
IF5.1
2025-01-280
OAAI
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients

评估自然语言处理提取数据在晚期肺癌患者中的可行性与外部有效性

2025-01-010
OAAI
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

前20名EGFR NSCLC临床和转化科学论文,塑造了NSCLC中激活EGFR突变发现的20年。主编专家小组共识调查。

2024-06-010
OAAI
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy

外周免疫系统中对I型干扰素的预编码反应性定义了PD1阻断治疗的结果

2022-07-1427
PRE
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
2021-12-017
OA
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study
2021-01-0158
PREAI